[ccp4bb] Scientist Antibody Production at the Institute for Protein Innovation in Boston, USA

[Christopher Bahl]

Scientist Antibody Production

Reports to the Head of Biological Discovery, Dr. Rob Meijers

The Institute for Protein Innovation (IPI) is a nonprofit research
organization advancing protein science to accelerate research and improve
human health. Located on the Harvard Medical School campus in the Boston
Longwood Medical Area, IPI is pioneering a new way of doing science that
uniquely combines the freedom of academia with the high-throughput scaling
of industry to take on transformative projects.  IPI has built a robust
platform and a repository of synthetic antibodies and other protein tools
to share with the biomedical community through licensing and collaboration.
The Institute’s deep protein expertise, collaborative spirit and
fit-for-purpose antibodies are powering new biomedical and therapeutic
discoveries for academic and industrial researchers worldwide.


Job Overview

IPI’s flagship project, the “Antibody Initiative,” aims to create
well-characterized, synthetic antibodies against human cell surface
receptors and their ligands, particularly those that are traditionally
difficult to target. These antibodies may have high therapeutic and
diagnostic potential but will also serve to enable basic biological
discovery.

The Scientist, Antibody Production will play an essential role in the
high-throughput production, characterization and formulation of synthetic
antibodies for this Initiative and other key IPI projects. Specifically,
the successful candidate will join the Protein Group, a dynamic team
generating high-quality antibodies and developing new technologies for
conjugation.

Having completed a doctorate in protein chemistry, the successful candidate
will bring to the job experience in mammalian expression, purification and
reagent-grade preparation of glycoproteins. The candidate will be adept in
quality control and process management and reliably provide detailed
documentation on experiments completed.

The Scientist will work in close collaboration with the other Antibody
Initiative team members and enjoy the opportunity to contribute to a wide
array of novel biological discovery projects. As this position is highly
collaborative, strong communication skills are needed. The Scientist will
engage with outside collaborators, translate their biological questions
into novel protein reagents and share these reagents with the larger
research community through abstracts, presentations and publications.


Responsibilities and Duties

-Express, purify, and characterize glycoproteins from mammalian cells
-Leverage robotics and automation to increase the quality and throughput of
antibody production at IPI
-Formulate and package antibodies for use by collaborators and customers
-Supervise research associates and coordinate with other scientists to
ensure efficient, high-quality antibody production
-Actively lead the experimental design and data production for
collaborations and scientific publications
-Participate in meetings and conferences to engage and recruit outside
research groups to participate in the Antibody Initiative


Qualifications

-PhD degree in mammalian protein expression, protein biochemistry, or
structural biology
-Well acquainted with best practices in cell culture and reagent production
-Ability to work in a fast-paced, intellectually challenging environment
-Enthusiastic team member with a strong commitment to mission and a desire
to conduct impactful science
-Good organizational and documentation skills
-The ideal candidate will have recently completed a PhD and have a desire
to explore a more entrepreneurial position

IPI is an independent 501(3)(c) nonprofit research organization and an
equal opportunity employer. The Institute celebrates diversity and is
committed to creating an inclusive environment for all employees. If
interested, please email your resume to .

-- 

PLEASE NOTE: This message, including any attachments, may include 
privileged, confidential and/or inside information belonging to IPI. Any 
distribution or use of this communication by anyone other than the intended 
recipient(s) is strictly prohibited and may be unlawful. If you are not the 
intended recipient, please notify the sender by replying to this message 
and then delete it from your system. Thank you.




To unsubscribe from the CCP4BB list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1

This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list 
hosted by www.jiscmail.ac.uk, terms & conditions are available at 
https://www.jiscmail.ac.uk/policyandsecurity/


JD_Antibody_Scientist_F 012421.docx
Description: Binary data

Re: [ccp4bb] Contagious, Self-Distributing "Vaccines?"

[Patrick Shaw Stewart]

(Sorry - still off-topic - or not !)

Hi Jessica

There's something called the "transmission-virulence trade-off hypothesis",
which was introduced specifically to explain observations of myxoma virus
virulence in Australia.  What scientists found was that if they introduced
what they called Grade I (ie highly virulent) myxoma strains, they
recovered Grade III strains one or two years later.  But if they introduced
(very mild) Grade IV strains, they also recovered Grade III strains a
little later.  It always ended up as Grade III.  I discussed this in my
preprint - and also in the paper my collaborator and I are now working on !

So probably not a good idea Jacob

Thx Patrick



On Thu, Feb 18, 2021 at 4:16 PM Jessica Bruhn 
wrote:

> Hello,
>
> There have been some really excellent points raised by others (informed
> consent, feasibility, etc), but I would like to share a story about another
> time humans tried to release a virus on a wild population in order to
> further an arguably noble goal:
>
> In the 1850s European rabbits were introduced in Australia for sport
> hunting. They quickly did what bunnies do and started to become a real
> problem. In the 1950s, scientists decided to introduce myxoma virus to
> Australia, which is 90-99% fatal for European rabbits, but less lethal for
> the native rabbits. They intentionally released this virus and in the first
> year the mortality rate was 99.8% for the European rabbits. Yay, right???
> Unfortunately, in the subsequent year the mortality rate fell to 25% and
> steadily continued to fall until it was lower than the reproductive rate of
> the European rabbits. The host-virus interaction played itself out:
> less-virulent viruses arose and resistant rabbits were selected for.
>
> To me it seems unwise to assume a replication competent virus (engineered
> or not) would refrain from mutating and adapting upon release, especially
> over the time course that would be required to infect all 7 billion+ humans
> on this planet. To me, I feel our options are (1) reach herd immunity
> through natural infection and accept the preventable deaths of many
> millions of people or (2) continue with non-pharmaceutical interventions
> (mask wearing, distancing, etc) until we can vaccinate enough people to
> reach herd immunity and hopefully by that time we have robust testing and
> treatment options available for those who continue to fall ill after we
> reach herd immunity. We as humans did something amazing by producing
> multiple safe and effective vaccines in less than one year, and I would
> like us to continue trying to save as many lives as possible by employing
> these vaccines as widely as possible.
>
> Anyways, take care. I know the pandemic is hard on all of us.
>
> Best regards,
> Jessica
>
> On Thu, Feb 18, 2021 at 6:15 AM Patrick Shaw Stewart <
> patr...@douglas.co.uk> wrote:
>
>> I agree with those who say that A and B are usually incompatible.
>>
>> If we're like chickens-in-a-barn-that-have-been-infected-with-bird-flu,
>> the virus very rapidly becomes more virulent (hospital and care-home
>> infections?).  It's hard for a virus to infect your nose and throat
>> quickly, and then stop.
>>
>> In the medium term the herd will build up some immunity and then we'll
>> become more like wandering albatrosses: the virus has to keep us on the
>> move if it's going to get itself near another susceptible host.
>>
>> IMO the way a *respiratory *virus tries to "have its cake and eat it" -
>> that is, get as much of both A and B as possible - is to develop thermal
>> sensitivity.  I.e. infect nose and throat but keep out of lungs and brain :
>>
>> https://www.preprints.org/manuscript/202101.0389/v1
>>
>>
>>
>> Thanks, Patrick
>>
>>
>> On Wed, Feb 17, 2021 at 9:46 PM Edwin Pozharski 
>> wrote:
>>
>>> I guess for such vehicle to be "extremely contagious" (or contagious at
>>> all for that matter) it should be capable of rapidly multiplying inside the
>>> host, so that it outruns immune system mediated destruction for at least
>>> some time in order to be present in high enough concentration to
>>> effectively spread via aerosols.  Given the range of immunodeficiencies
>>> present in any population, you are essentially guaranteed to kill at least
>>> some people whose immune system will not be able to cope with rapidly
>>> multiplying virus.  You can theoretically fine tune the lethality of such
>>> virus to make sure that number of people you thus murder will be less than
>>> those that die either in no vaccine or traditional vaccination scenario,
>>> but that would be ethical equivalent of that modern crypto fascist
>>> suggestion that we just have to take it easy until herd immunity is
>>> established, even though few million grandparents will die in the process
>>> while the rest of us enjoy indoor dining.
>>>
>>>
>>>
>>> On Wed, Feb 17, 2021 at 12:33 PM Jacob Keller 
>>> wrote:
>>>
 It would seem to me that it should be possible to generate versions of
 the 

[ccp4bb] Membrane Protein Biochemist Position at Sosei Heptares

[Mathieu Rappas]

We are now seeking a highly experienced membrane protein biochemist to join
the Biochemistry group at our research facility on Granta Park, Cambridge,
UK, working on membrane protein biochemical characterisation to enable drug
discovery efforts.

At Sosei Heptares we are equipped with state-of-the-art protein expression,
purification, SPR, mass-spectrometry, crystallisation and cryoEM
facilities. Applicants should have experience in the expression and
purification of challenging membrane proteins destined for biochemical,
biophysical and structural studies. Applicants should possess a proven
track record of publications related to the expression, purification, and
biochemical characterisation of difficult membrane protein targets in
peer-reviewed journals.

This is an exceptional opportunity to participate in pioneering science
with an industry-leading drug discovery company.

The successful candidate is expected to:

• Express and purify membrane proteins
• Perform appropriate quality control analyses and biochemically and
biophysically characterise purified membrane proteins
• Keep up to date, propose, develop, implement and optimise new techniques
in the fields of membrane protein expression, purification and biochemical
characterisation
• Work together with scientists responsible for successfully progressing
membrane protein targets through Sosei Heptares’ structure-based drug
design pipeline
• Collaborate with other Sosei Heptares scientists on research projects,
working closely with molecular biologists, biophysicists, structural
biologists, molecular pharmacologists, computational and medicinal chemists
• Prepare and effectively present results (written and oral) to project
teams
• Have strong interpersonal skills and interact effectively with
collaborators across a wide range of disciplines

Requirements:

The preferred candidate will have the following:

• Candidates should possess a PhD in biochemistry, biophysics or a related
discipline
• Candidates should have experience in membrane protein expression,
purification and characterisation in either an academic or industry setting
• Possess extensive molecular biology skills
• Knowledgeable in prokaryotic and eukaryotic expression vectors and be
experienced in their manipulation
• Well-versed in expression construct design and engineering to
successfully express membrane proteins destined for biochemical,
biophysical and structural studies
• Expert in the expression of membrane proteins from mammalian and insect
cells
• Proficient in the purification and extensive biochemical characterisation
of membrane proteins
• Experienced in the reconstitution of purified membrane proteins in
membrane-mimetic environments
• Familiar with biochemical and biophysical techniques used to characterise
membrane proteins such as luminescence, fluorescence and FRET-based
techniques
• Candidates should understand the requirements of purified membrane
proteins destined for structural (X-ray and/or CryoEM) and biophysical
studies (SPR, mass spectrometry)
• Candidates should be highly organised

Other information

The successful candidate will be employed by Heptares Therapeutics Ltd, a
UK wholly owned subsidiary of Sosei Group Corporation.

We offer a competitive salary, commensurate with qualifications and
experience, and benefits package including pension and healthcare schemes.

Applications should include a covering letter, providing a short
description of the background to their interest in the role, with
curriculum vitae including the names and contact details for two referees.
Please apply through our on-line jobs portal with your application in pdf
format, quoting reference number 2021-2BMS.

The closing date for applications is 30th March 2021. Strictly no agencies



To unsubscribe from the CCP4BB list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1

This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list 
hosted by www.jiscmail.ac.uk, terms & conditions are available at 
https://www.jiscmail.ac.uk/policyandsecurity/

[ccp4bb] Rigaku CrystalTrak Web not working

[Pavel Mader]

Hello everyone,



is there anyone else, who is using Rigaku CrystalTrak Web system (in our 
case version 2.3.4) for checking images of crystallization experiments? 
Recently (on January 14, 2021) the Adobe has stopped supporting the Flash 
support needed for the CrystalTrak web version from being fully functional.




Is there anyone else, who has been facing this problem? Is there any good 
solution?




Thanks,




Pavel Mader



To unsubscribe from the CCP4BB list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1

This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list 
hosted by www.jiscmail.ac.uk, terms & conditions are available at 
https://www.jiscmail.ac.uk/policyandsecurity/

Re: [ccp4bb] Coot/Phenix.refine C-terminus issue

[Neno Vuksanovic]

 Dear All,

Thank you so much for the suggestions. There was indeed a TER in my PDB
file and removing it solved the problem. I was using Coot 0.8.9.2.

Best Regards,
Nen

On Thu, Feb 18, 2021 at 11:07 AM Paul Emsley 
wrote:

> On 18/02/2021 15:21, Neno Vuksanovic wrote:
> >
> > I've been having an issue when manually adding C-terminal residue in
> Coot (I add a terminal residue, then
> > add OXT atom, and perform real space refinement). The residue links the
> previous one properly and the
> > density matches it well, but after refining in Phenix.refine, the
> residue is unconnected from the rest of
> > the chain. The log file does not mention having any issues with it. Do I
> need to change the linking settings
> > in Phenix.refine and what could be causing the issue?
> >
>
> Why don't you tell us which version of Coot that you're using?
>
> Old Coots used to not properly handle TER records on chain extension.
> Maybe it's that.
>
> Paul.
>
> 
>
> To unsubscribe from the CCP4BB list, click the following link:
> https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1
>
> This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a
> mailing list hosted by www.jiscmail.ac.uk, terms & conditions are
> available at https://www.jiscmail.ac.uk/policyandsecurity/
>



To unsubscribe from the CCP4BB list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1

This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list 
hosted by www.jiscmail.ac.uk, terms & conditions are available at 
https://www.jiscmail.ac.uk/policyandsecurity/

Re: [ccp4bb] Contagious, Self-Distributing "Vaccines?"

[Jessica Bruhn]

Hello,

There have been some really excellent points raised by others (informed
consent, feasibility, etc), but I would like to share a story about another
time humans tried to release a virus on a wild population in order to
further an arguably noble goal:

In the 1850s European rabbits were introduced in Australia for sport
hunting. They quickly did what bunnies do and started to become a real
problem. In the 1950s, scientists decided to introduce myxoma virus to
Australia, which is 90-99% fatal for European rabbits, but less lethal for
the native rabbits. They intentionally released this virus and in the first
year the mortality rate was 99.8% for the European rabbits. Yay, right???
Unfortunately, in the subsequent year the mortality rate fell to 25% and
steadily continued to fall until it was lower than the reproductive rate of
the European rabbits. The host-virus interaction played itself out:
less-virulent viruses arose and resistant rabbits were selected for.

To me it seems unwise to assume a replication competent virus (engineered
or not) would refrain from mutating and adapting upon release, especially
over the time course that would be required to infect all 7 billion+ humans
on this planet. To me, I feel our options are (1) reach herd immunity
through natural infection and accept the preventable deaths of many
millions of people or (2) continue with non-pharmaceutical interventions
(mask wearing, distancing, etc) until we can vaccinate enough people to
reach herd immunity and hopefully by that time we have robust testing and
treatment options available for those who continue to fall ill after we
reach herd immunity. We as humans did something amazing by producing
multiple safe and effective vaccines in less than one year, and I would
like us to continue trying to save as many lives as possible by employing
these vaccines as widely as possible.

Anyways, take care. I know the pandemic is hard on all of us.

Best regards,
Jessica

On Thu, Feb 18, 2021 at 6:15 AM Patrick Shaw Stewart 
wrote:

> I agree with those who say that A and B are usually incompatible.
>
> If we're like chickens-in-a-barn-that-have-been-infected-with-bird-flu,
> the virus very rapidly becomes more virulent (hospital and care-home
> infections?).  It's hard for a virus to infect your nose and throat
> quickly, and then stop.
>
> In the medium term the herd will build up some immunity and then we'll
> become more like wandering albatrosses: the virus has to keep us on the
> move if it's going to get itself near another susceptible host.
>
> IMO the way a *respiratory *virus tries to "have its cake and eat it" -
> that is, get as much of both A and B as possible - is to develop thermal
> sensitivity.  I.e. infect nose and throat but keep out of lungs and brain :
>
> https://www.preprints.org/manuscript/202101.0389/v1
>
>
>
> Thanks, Patrick
>
>
> On Wed, Feb 17, 2021 at 9:46 PM Edwin Pozharski 
> wrote:
>
>> I guess for such vehicle to be "extremely contagious" (or contagious at
>> all for that matter) it should be capable of rapidly multiplying inside the
>> host, so that it outruns immune system mediated destruction for at least
>> some time in order to be present in high enough concentration to
>> effectively spread via aerosols.  Given the range of immunodeficiencies
>> present in any population, you are essentially guaranteed to kill at least
>> some people whose immune system will not be able to cope with rapidly
>> multiplying virus.  You can theoretically fine tune the lethality of such
>> virus to make sure that number of people you thus murder will be less than
>> those that die either in no vaccine or traditional vaccination scenario,
>> but that would be ethical equivalent of that modern crypto fascist
>> suggestion that we just have to take it easy until herd immunity is
>> established, even though few million grandparents will die in the process
>> while the rest of us enjoy indoor dining.
>>
>>
>>
>> On Wed, Feb 17, 2021 at 12:33 PM Jacob Keller 
>> wrote:
>>
>>> It would seem to me that it should be possible to generate versions of
>>> the Covid virus that would:
>>>
>>> A. be extremely contagious and yet
>>> B. be clinically benign, and
>>> C. confer immunity to the original covid virus.
>>>
>>> If, then, this virus could be released, with appropriate "kill switch"
>>> safeguards built in, would this not solve the world's pandemic problems? Is
>>> there any reason, practically, why this approach would not be feasible?
>>>
>>> Maybe we don't really know enough to manipulate A, B, C yet?
>>>
>>> Or maybe it's too scary for primetime...nightmare bio-warfare apocalypse?
>>>
>>> Has this sort of thing been done, or does it have a name?
>>>
>>> Jacob
>>> --
>>>
>>> +
>>>
>>> Jacob Pearson Keller
>>>
>>> Assistant Professor
>>>
>>> Department of Pharmacology and Molecular Therapeutics
>>>
>>> Uniformed Services University
>>>
>>> 4301 Jones Bridge Road
>>>
>>> Bethesda 

Re: [ccp4bb] Coot/Phenix.refine C-terminus issue

[Paul Emsley]

On 18/02/2021 15:21, Neno Vuksanovic wrote:


I've been having an issue when manually adding C-terminal residue in Coot (I add a terminal residue, then 
add OXT atom, and perform real space refinement). The residue links the previous one properly and the 
density matches it well, but after refining in Phenix.refine, the residue is unconnected from the rest of 
the chain. The log file does not mention having any issues with it. Do I need to change the linking settings 
in Phenix.refine and what could be causing the issue?




Why don't you tell us which version of Coot that you're using?

Old Coots used to not properly handle TER records on chain extension. Maybe 
it's that.

Paul.



To unsubscribe from the CCP4BB list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1

This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list 
hosted by www.jiscmail.ac.uk, terms & conditions are available at 
https://www.jiscmail.ac.uk/policyandsecurity/

[ccp4bb] Coot/Phenix.refine C-terminus issue

[Neno Vuksanovic]

 Dear All,

I've been having an issue when manually adding C-terminal residue in Coot
(I add a terminal residue, then add OXT atom, and perform real space
refinement). The residue links the previous one properly and the density
matches it well, but after refining in Phenix.refine, the residue is
unconnected from the rest of the chain. The log file does not mention
having any issues with it. Do I need to change the linking settings in
Phenix.refine and what could be causing the issue?

Best regards,
Neno



To unsubscribe from the CCP4BB list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1

This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list 
hosted by www.jiscmail.ac.uk, terms & conditions are available at 
https://www.jiscmail.ac.uk/policyandsecurity/

[ccp4bb] Virtual Workshop „Strategy for future EMBL research infrastructures in the Life Sciences in Hamburg“, 29.-30.3.2021

[Margret Fischer]

Dear Colleagues,

We are pleased to announce the virtual *Workshop **„**Strategy for 
future EMBL research infrastructures in the Life Sciences in 
Hamburg**“*taking place on Monday, 29th and Tuesday, 30th March 2021.
The aim of this workshop is to explore possible future directions for 
research and research services in structural biology. All interested 
scientists (user community, stake holders, funding organisations etc.)
are most cordially invited to participate. Details about the workshop 
can be found at https://indico.embl-hamburg.de/event/2/ 
. The registration is open on a 
first come first serve basis with a limited number of places available.


best wishes,

Margret

on behalf of the workshop organisers: Thomas Schneider, Dmitri Svergun 
and Matthias Wilmanns


--

Margret Fischer
European Molecular Biology Laboratory
Senior Administrative Officer
Notkestrasse 85
22607 Hamburg
Germany
Tel: +49 40 89902110
Mob: +49 1754105760



To unsubscribe from the CCP4BB list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1

This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list 
hosted by www.jiscmail.ac.uk, terms & conditions are available at 
https://www.jiscmail.ac.uk/policyandsecurity/

Re: [ccp4bb] Contagious, Self-Distributing "Vaccines?"

[Patrick Shaw Stewart]

I agree with those who say that A and B are usually incompatible.

If we're like chickens-in-a-barn-that-have-been-infected-with-bird-flu, the
virus very rapidly becomes more virulent (hospital and care-home
infections?).  It's hard for a virus to infect your nose and throat
quickly, and then stop.

In the medium term the herd will build up some immunity and then we'll
become more like wandering albatrosses: the virus has to keep us on the
move if it's going to get itself near another susceptible host.

IMO the way a *respiratory *virus tries to "have its cake and eat it" -
that is, get as much of both A and B as possible - is to develop thermal
sensitivity.  I.e. infect nose and throat but keep out of lungs and brain :

https://www.preprints.org/manuscript/202101.0389/v1



Thanks, Patrick


On Wed, Feb 17, 2021 at 9:46 PM Edwin Pozharski 
wrote:

> I guess for such vehicle to be "extremely contagious" (or contagious at
> all for that matter) it should be capable of rapidly multiplying inside the
> host, so that it outruns immune system mediated destruction for at least
> some time in order to be present in high enough concentration to
> effectively spread via aerosols.  Given the range of immunodeficiencies
> present in any population, you are essentially guaranteed to kill at least
> some people whose immune system will not be able to cope with rapidly
> multiplying virus.  You can theoretically fine tune the lethality of such
> virus to make sure that number of people you thus murder will be less than
> those that die either in no vaccine or traditional vaccination scenario,
> but that would be ethical equivalent of that modern crypto fascist
> suggestion that we just have to take it easy until herd immunity is
> established, even though few million grandparents will die in the process
> while the rest of us enjoy indoor dining.
>
>
>
> On Wed, Feb 17, 2021 at 12:33 PM Jacob Keller 
> wrote:
>
>> It would seem to me that it should be possible to generate versions of
>> the Covid virus that would:
>>
>> A. be extremely contagious and yet
>> B. be clinically benign, and
>> C. confer immunity to the original covid virus.
>>
>> If, then, this virus could be released, with appropriate "kill switch"
>> safeguards built in, would this not solve the world's pandemic problems? Is
>> there any reason, practically, why this approach would not be feasible?
>>
>> Maybe we don't really know enough to manipulate A, B, C yet?
>>
>> Or maybe it's too scary for primetime...nightmare bio-warfare apocalypse?
>>
>> Has this sort of thing been done, or does it have a name?
>>
>> Jacob
>> --
>>
>> +
>>
>> Jacob Pearson Keller
>>
>> Assistant Professor
>>
>> Department of Pharmacology and Molecular Therapeutics
>>
>> Uniformed Services University
>>
>> 4301 Jones Bridge Road
>>
>> Bethesda MD 20814
>>
>> jacob.kel...@usuhs.edu; jacobpkel...@gmail.com
>>
>> Cell: (301)592-7004
>>
>> +
>>
>> --
>>
>> To unsubscribe from the CCP4BB list, click the following link:
>> https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1
>>
>
> --
>
> To unsubscribe from the CCP4BB list, click the following link:
> https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1
>


-- 
 patr...@douglas.co.ukDouglas Instruments Ltd.
 Douglas House, East Garston, Hungerford, Berkshire, RG17 7HD, UK
 Directors: Patrick Shaw Stewart, Peter Baldock, Stefan Kolek

 http://www.douglas.co.uk
 Tel: 44 (0) 148-864-9090US toll-free 1-877-225-2034
 Regd. England 2177994, VAT Reg. GB 480 7371 36



To unsubscribe from the CCP4BB list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1

This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list 
hosted by www.jiscmail.ac.uk, terms & conditions are available at 
https://www.jiscmail.ac.uk/policyandsecurity/

Re: [ccp4bb] Contagious, Self-Distributing "Vaccines?"

[Gerstel, Markus (DLSLtd,RAL,LSCI)]

Dale Tronrud wrote:
> The live form of the polio virus is the closest I know to the vaccination 
> campaign you describe. 

I know something closer - it was called Welchia/Nachi and appeared in 2003
https://en.wikipedia.org/wiki/Welchia

This did spark ethics discussions even when in this case human lives weren't 
(directly) at stake. As far as I can tell the consensus ultimately was that 
this is a bad idea, and it was noted that even the most well-intentioned effort 
can and will go wrong.
https://www.technologyreview.com/2009/01/23/267877/why-a-good-worm-may-be-a-bad-idea/

Consent is of course the obvious primary concern. But can you also guarantee 
that your super-virus is clinically benign in everyone? (think: pregnant, 
neonatal, immuno-compromised, hypersensitive) And also: how could you prove 
that when your Phase 1 trial involves... literally everyone?

I'm actually a trained vaccinator now, and we go to great lengths to only 
administer vaccines in very controlled settings. Apart from consent the 
administration is also controlled by a risk assessment regarding sensitivity to 
the vaccine and any of its ingredients, and we also observe people afterwards - 
so that in the rare case they do have an anaphylactoid reaction, vasovagal 
response, panic attack or anything else - immediate help is at hand.
When people do suffer slower side-effects then you might be able to ascribe 
them to the vaccination. In any case you can go straight to the MHRA yellow 
card scheme. In the super-virus case you'd need to test people first. And I was 
under the impression that our health services are already quite busy.

Speaking of side-effects - what side-effects would this campaign cause? And I 
don't mean just the individual/physiological. Think chemtrailers etc. - they 
would have a field day. Trust in medicine would take a nosedive for decades to 
come.

So yeah - let's not do that.

-Markus

-- 
This e-mail and any attachments may contain confidential, copyright and or 
privileged material, and are for the use of the intended addressee only. If you 
are not the intended addressee or an authorised recipient of the addressee 
please notify us of receipt by returning the e-mail and do not use, copy, 
retain, distribute or disclose the information in or attached to the e-mail.
Any opinions expressed within this e-mail are those of the individual and not 
necessarily of Diamond Light Source Ltd. 
Diamond Light Source Ltd. cannot guarantee that this e-mail or any attachments 
are free from viruses and we cannot accept liability for any damage which you 
may sustain as a result of software viruses which may be transmitted in or with 
the message.
Diamond Light Source Limited (company no. 4375679). Registered in England and 
Wales with its registered office at Diamond House, Harwell Science and 
Innovation Campus, Didcot, Oxfordshire, OX11 0DE, United Kingdom




To unsubscribe from the CCP4BB list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1

This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list 
hosted by www.jiscmail.ac.uk, terms & conditions are available at 
https://www.jiscmail.ac.uk/policyandsecurity/

Re: [ccp4bb] Contagious, Self-Distributing "Vaccines?"

[Harmer, Nicholas]

I'm afraid that the "Kent" variant is also mutating and is likely to pick up 
some of the more challenging mutations. There is already a version circulating 
with the E484 mutation that has a clear impact on the vaccine ("Bristol" 
variant), and another picked up in Scotland that has several changes similar to 
the SA variant.

The UK is sequencing a _lot_ and picking up a lot of changes. Probably the 
message is that if a virus new to humans circulates enough, it's going to 
mutate to find its optimal niche.

Nic

-Original Message-
From: CCP4 bulletin board  On Behalf Of Ethan A Merritt
Sent: 17 February 2021 20:57
To: CCP4BB@JISCMAIL.AC.UK
Subject: Re: [ccp4bb] Contagious, Self-Distributing "Vaccines?"

It may be here already.

For a value of B that includes "no worse than the starting point", the 
so-called "UK variant" currently spreading in the US meets your criteria.  Some 
projections show it displacing other potentially more dangerous variants while 
not not degrading the impact of vaccination and other public health measures.

Are you starting a conspiracy theory that it was the result of a clandestine 
good samaritan molecular biologist?

Ethan

On Wednesday, 17 February 2021 12:39:21 PST Jacob Keller wrote:
> I was under the impression that A,B,C are not strongly or 
> intrinsically coupled, for one, since there are so many varieties of 
> viruses with so much range of infectiousness and clinical severity. False 
> impression?
> 
> B + C = vaccine
> 
> A + B + C = immunosysadmin pandemic updater virus. Patient 0 honors 
> given for each (yearly?) edition to curry political favor.
> 
> JPK
> 
> 
> On Wed, Feb 17, 2021 at 3:03 PM Tim Gruene  wrote:
> 
> > Hi Jacob,
> >
> > how do you think this should be possible? In order to infect others, 
> > the virus particle needs to proliferate (that's the only thing it 
> > does). It profilerates by hijacking the machinery of one cell of 
> > your body and turn it into a virus factory. Your body does not like 
> > this abuse and kills the cell, and also tries to kill the virus particles.
> > The virus does not make you sick, it only captures one cell. The 
> > reaction of your body to kick out the virus, and the cell that does 
> > not do it's job anymore, make you sick. A and B are mutually 
> > exclusive. B + C is named vaccine.
> >
> > Best,
> > Tim
> >
> >
> > On Wed, 17 Feb 2021 12:33:09 -0500 Jacob Keller 
> >  wrote:
> >
> > > It would seem to me that it should be possible to generate 
> > > versions of the Covid virus that would:
> > >
> > > A. be extremely contagious and yet B. be clinically benign, and C. 
> > > confer immunity to the original covid virus.
> > >
> > > If, then, this virus could be released, with appropriate "kill switch"
> > > safeguards built in, would this not solve the world's pandemic 
> > > problems? Is there any reason, practically, why this approach 
> > > would not be feasible?
> > >
> > > Maybe we don't really know enough to manipulate A, B, C yet?
> > >
> > > Or maybe it's too scary for primetime...nightmare bio-warfare 
> > > apocalypse?
> > >
> > > Has this sort of thing been done, or does it have a name?
> > >
> > > Jacob
> >
> >
> >
> > --
> > --
> > Tim Gruene
> > Head of the Centre for X-ray Structure Analysis Faculty of Chemistry 
> > University of Vienna
> >
> > Phone: +43-1-4277-70202
> >
> > GPG Key ID = A46BEE1A
> >
> 
> 
> 


--
Ethan A Merritt
Biomolecular Structure Center,  K-428 Health Sciences Bldg
MS 357742,   University of Washington, Seattle 98195-7742



To unsubscribe from the CCP4BB list, click the following link:
https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.jiscmail.ac.uk%2Fcgi-bin%2FWA-JISC.exe%3FSUBED1%3DCCP4BB%26A%3D1data=04%7C01%7CN.J.Harmer%40exeter.ac.uk%7C4b309b2facb84ecfbf4208d8d387103b%7C912a5d77fb984eeeaf321334d8f04a53%7C0%7C0%7C637491924339146877%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000sdata=%2BE%2BP%2BFmT3ssBHfhdafYUaDE0yb0Z2vTmlRTTG7HD48w%3Dreserved=0

This message was issued to members of 
https://eur03.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.jiscmail.ac.uk%2FCCP4BBdata=04%7C01%7CN.J.Harmer%40exeter.ac.uk%7C4b309b2facb84ecfbf4208d8d387103b%7C912a5d77fb984eeeaf321334d8f04a53%7C0%7C0%7C637491924339146877%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000sdata=zlAw%2F95oetjwm9N8y0u9vUju4qdqf7iy22aTeOrrlOY%3Dreserved=0,
 a mailing list hosted by 
https://eur03.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.jiscmail.ac.uk%2Fdata=04%7C01%7CN.J.Harmer%40exeter.ac.uk%7C4b309b2facb84ecfbf4208d8d387103b%7C912a5d77fb984eeeaf321334d8f04a53%7C0%7C0%7C637491924339146877%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000sdata=dosEZcaSlYwjZCR4Rf1X6vgyioWwQV0cNt3SSzhV7vk%3Dreserved=0,
 terms & conditions are